Fate Therapeutics, Inc. (FATE): $84.76

1.23 (+1.47%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add FATE to Watchlist
Sign Up

Industry: Biotech


Ranked

of 487

in industry

Fate Therapeutics Inc (FATE) Price Targets From Analysts

Use the tables below to see what analysts covering Fate Therapeutics Inc think about its future price and what recommendations they have for investors and traders.

Number of Analysts Highest Target Price Lowest Target Price Average Target Price Current Price Upside Potential
17 $145 $71 $111 $86.79 27.89%

The Trend in the Analyst Price Target


Over the past 28 weeks, FATE's average price target has gone up $57.46.

FATE reports an average of 10.8% for its upside potential over the past 52 weeks.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Share Price Upside Potential
2021-06-04 17 145 71 111.00 72.79 52.49%
2021-04-19 17 135 88 113.65 79.65 42.69%
2021-04-17 17 135 88 113.65 81.17 40.01%
2021-03-15 17 135 88 113.65 92.77 22.51%
2021-03-13 17 135 88 113.65 93.99 20.92%
2021-01-13 16 118 30 81.75 113.29 -27.84%
2021-01-09 16 118 30 81.75 116.31 -29.71%
2021-01-02 16 118 30 78.88 90.93 -13.25%
2020-11-23 14 71 30 54.36 54.29 0.13%
2020-11-20 13 71 30 53.54 52.65 1.69%
2020-11-14 14 71 30 52.57 50.51 4.08%
2020-10-26 16 60 29 42.12 46.90 -10.19%
2020-09-07 16 59 29 39.50 31.11 26.97%
2020-08-22 16 59 29 39.62 36.12 9.69%
2020-08-12 16 59 29 39.62 34.11 16.15%
2020-08-06 16 59 29 38.94 33.42 16.52%
2020-06-16 16 59 29 38.81 NA NA%
2020-06-16 17 59 29 39.00 NA NA%
2020-06-08 17 59 29 39.00 NA NA%

FATE Broker Recommendations Summary

Average Broker Rating Strong Buy Buy Hold Sell Strong Sell Analysts Issuing Recs
1.47 6 6 5 0 0 17

Use the points listed below to better contextualize what this analyst price target and recommendations data data means for investors.

  • The number of analysts covering the stock of FATE is higher than 89.62% of all US stocks.
  • Fate Therapeutics Inc's average analyst price target is greater than 93.38% of Pharmaceutical Products stocks.
  • Fate Therapeutics Inc's variance in analysts' estimates is lower than 13.76% of stocks in the mid market cap category.
  • The upside potential (average analyst target price relative to current price) of FATE is higher than 20.72% of Pharmaceutical Products stocks.

In terms of price targets and recommendations offered by analysts, the stocks in the Pharmaceutical Products industry with the ratings most similar to Fate Therapeutics Inc are BMY, JNJ and BPMC.

Is FATE a Buy, Hold or Sell? See the POWR Ratings now!


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.7211 seconds.